Microstructural alterations in white matter and related neurobiology based on the new clinical subtypes of

Xiaorong Yuan1, Qiaowen Yu1,2, Yanyan Liu1

  • 1Department of Medical Imaging, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.

PubMed
Abstract

Insights

Diffusion tensor imaging (DTI) aids in early Parkinson's disease (PD) diagnosis by detecting white matter damage. DTI effectively predicts clinical progression and cognitive outcomes in PD subtypes, particularly the diffuse malignant (PD-DM) group.

Area of Science:

  • Neuroimaging
  • Neurology
  • Biomarkers

Background:

  • New clinical subtyping systems classify Parkinson's disease (PD) into mild motor predominant (PD-MMP), intermediate (PD-IM), and diffuse malignant (PD-DM) subtypes.
  • Understanding the pathological mechanisms and early diagnostic markers for these PD subtypes is crucial for effective management.

Purpose of the Study:

  • Evaluate diffusion tensor imaging (DTI) for early diagnosis, clinical progression assessment, and prognosis prediction in PD subtypes.
  • Investigate white matter damage mechanisms using DTI, single-photon emission computed tomography (SPECT), and cerebrospinal fluid (CSF) analyses.

Main Methods:

  • Classified 135 de novo PD patients and 45 healthy controls (HCs) based on new clinical criteria.
  • Utilized tract-based spatial statistics for white matter microstructural analysis and multiple linear regression for associations between DTI metrics and clinical data.

Main Results:

  • PD-DM subtype showed reduced fractional anisotropy (FA) and increased axial (AD) and radial diffusivity (RD) compared to HCs.
  • FA and RD correlated with motor symptoms and cognitive performance; FA changes tracked motor score progression.
  • AD changes related to semantic verbal fluency, and FA linked to alpha-synuclein and beta-amyloid levels.

Conclusions:

  • The PD-DM subtype exhibits severe symptoms and rapid progression.
  • DTI facilitates early identification of white matter damage, elucidates disease mechanisms, and predicts cognitive outcomes in PD.
  • SPECT and CSF analyses can explain specific white matter damage patterns in PD-DM.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
501
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
240
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456